Dogwood Completes Enrollment in Halneuron Phase 2b Trial, Topline Data Due November
DWTX sits 59% above its 52-week low of $1.28.
Summary
Dogwood has completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, reaching the upper end of its target range with 239 patients. Topline data is expected in November 2026. This is a key milestone for the company, which has no FDA-approved treatments for CINP and faces a going concern warning with cash only funding operations into Q4 2026. Positive results could significantly de-risk the pipeline and attract financing, while failure would be a major setback. The company's CEO cited encouraging interim analysis, but no data was disclosed. The next major catalyst is the November data readout.
At the time of this announcement, DWTX was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.9M. The 52-week trading range was $1.28 to $9.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.